Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 70.9894
- Book/Share 38.2151
- PB 8.1562
- Debt/Equity 0.5957
- CurrentRatio 0.7761
- ROIC 0.3599
- MktCap 1385478304840.9907
- FreeCF/Share 14.1116
- PFCF 22.0839
- PE 13.3532
- Debt/Assets 0.1976
- DivYield 0.0348
- ROE 0.6695
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | NVO | Jefferies | -- | Underperform | -- | -- | Oct. 27, 2025 |
| Upgrade | NVO | HSBC Securities | Hold | Buy | -- | -- | Oct. 1, 2025 |
| Downgrade | NVO | Morgan Stanley | Equal Weight | Underweight | -- | $47 | Sept. 29, 2025 |
| Upgrade | NVO | Berenberg | Hold | Buy | -- | -- | Sept. 17, 2025 |
| Upgrade | NVO | Rothschild & Co Redburn | Neutral | Buy | -- | -- | Sept. 16, 2025 |
| Upgrade | NVO | Bernstein | Market Perform | Outperform | -- | -- | Sept. 9, 2025 |
| Upgrade | NVO | BNP Paribas Exane | Underperform | Neutral | -- | $54 | Aug. 13, 2025 |
| Downgrade | NVO | UBS | Buy | Neutral | -- | -- | Aug. 5, 2025 |
| Downgrade | NVO | HSBC Securities | Buy | Hold | -- | $57 | July 31, 2025 |
| Downgrade | NVO | Barclays | Overweight | Equal Weight | -- | -- | July 30, 2025 |
News
Novo Nordisk Stock Is a Better Obesity Play Than Eli Lilly, Berenberg Says
Published: September 17, 2025 by: Barrons
Sentiment: Positive
Novo Nordisk is “no longer the elephant in the room,” Berenberg analysts say.
Read More
NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity
Published: September 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk stock rises as its next-generation subcutaneous obesity treatment candidate, cagrilintide, delivers meaningful weight loss in a phase III obesity study.
Read More
GLP-1 drugs could save millions of lives — and spark a pension crisis
Published: September 17, 2025 by: Market Watch
Sentiment: Neutral
GLP-1 drugs are so powerful that, in 20 years, they can save millions from premature death, a leading insurance company says.
Read More
Novo Nordisk finds its footing again
Published: September 17, 2025 by: Proactive Investors
Sentiment: Positive
After a bruising year, Novo Nordisk (NYSE:NVO) is back in favour. Berenberg has upgraded the Danish drugmaker to 'buy', setting a target price of DKK425 against a current DKK359.
Read More
Eli Lilly's obesity pill outperforms Novo Nordisk's oral drug in head-to-head diabetes trial
Published: September 17, 2025 by: CNBC
Sentiment: Positive
Eli Lilly said its experimental pill outperformed Novo Nordisk's own oral drug in the first head-to-head study comparing the two medicines in patients with Type 2 diabetes. Eli Lilly said its pill, orforglipron, was superior at the trial's main goal of lowering blood sugar levels at 52 weeks compared to Novo Nordisk's oral semaglutide, and helped patients lose more weight.
Read More
NOVO NORDISK A/S (NYSE: NVO) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by September 30, 2025
Published: September 17, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Sept. 17, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S (NYSE: NVO) ("Novo" or the "Company"), a global pharmaceutical company, headquartered in Denmark, after a class action lawsuit was filed against Novo.
Read More
DEADLINE ALERT for SOC, LMT, NVO, and LINE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Published: September 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Read More
"Reassessment" of LLY & NVO GLP-1 Projections Set New Guidance Tone
Published: September 16, 2025 by: Schwab Network
Sentiment: Positive
Lee Brown offers investor insight in the GLP-1 space in what he calls an industry with "expanding opportunity." He believes consumer sentiment has reset to proper expectations following sell-offs in Eli Lilly (LLY) and Novo Nordisk (NVO), anticipating significant upside following the repricing.
Read More
Novo Nordisk Stock Rises on Trial Results for Cagrilintide Obesity Treatment
Published: September 16, 2025 by: Investopedia
Sentiment: Positive
U.S.-listed shares of Novo Nordisk (NVO) gained after the drugmaker reported positive results from a late-stage study of a weight-loss drug that works differently than traditional GLP-1 inhibitors.
Read More
Novo Nordisk shares higher on positive Phase 3 trial results for obesity drug Cagrilintide
Published: September 16, 2025 by: Proactive Investors
Sentiment: Positive
Novo Nordisk (NYSE:NVO) shares gained on Tuesday after the company reported promising Phase 3 trial results for its experimental weight-loss drug Cagrilintide, presented at the European Association for the Study of Diabetes congress in Vienna. The REDEFINE 1 trial showed that once-weekly injections of Cagrilintide led to an average 11.8% reduction in body weight over 68 weeks, compared with 2.3% in the placebo group.
Read More
Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk gains EU approval for adding the cardiovascular indication to Rybelsus' label, strengthening its edge in the competitive diabetes market.
Read More
Novo Nordisk: The Market Is Giving Us A Free Lunch
Published: September 15, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S's stock is severely oversold as the market overreacts to short-term news, which has created what appears to be a rare buying opportunity. While Q2 guidance was lowered, the underlying business remains strong with 18% year-over-year sales growth, proving that NVO's core momentum is still intact. Strategic catalysts like the exclusive CVS formulary win and the NovoCare direct-to-patient channel are actively working to secure future revenue and protect market share.
Read More
NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: September 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or “the Company”) (NYSE: NVO) and certain of its officers.
Read More
Novo Nordisk Stock Rises. Its Diabetes Pill Cleared a Key Hurdle.
Published: September 15, 2025 by: Barrons
Sentiment: Positive
Clinical trial results that showed the treatment reduced cardiovascular death, heart attack and stroke by 14% compared with placebo.
Read More
Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug battleground
Published: September 12, 2025 by: CNBC
Sentiment: Neutral
Eli Lilly and Novo Nordisk are both preparing to launch obesity pills in the U.S. next year. Lilly expects results from a head-to-head trial of its pill orforglipron versus Novo's oral semaglutide in the coming months, said Lilly's Chief Scientific Officer Dan Skovronsky.
Read More
ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO
Published: September 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the “Class Period”), of the important September 30, 2025 lead plaintiff deadline.
Read More
DEADLINE ALERT for SOC, LMT, NVO, and LINE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Published: September 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Sept. 11, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Read More
Novo Nordisk tells staff to return to office full-time amid CEO's revival effort
Published: September 11, 2025 by: Reuters
Sentiment: Neutral
Wegovy-maker Novo Nordisk said on Thursday it had told all its staff to return to the office as the drugmaker's new CEO tries to accelerate decision-making and improve its commercial execution amid intense competition in the obesity drug market.
Read More
Novo Nordisk layoffs: 9,000 jobs cut as weight-loss drug competition with Eli Lilly heats up
Published: September 10, 2025 by: Fast Company
Sentiment: Negative
Novo Nordisk, the Danish pharmaceutical giant behind the popular weight-loss drugs Ozempic and Wegovy, just announced plans to cut 11% of its workforce as competitors like Eli Lilly continue to encroach on its market share.
Read More
Shareholders that lost money on Novo Nordisk A/S(NVO) should contact The Gross Law Firm about pending Class Action - NVO
Published: September 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
Read More
Novo Nordisk: Restructuring And Reduced Guidance Set Up A Cleaner 2026
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Novo Nordisk A/S's job cuts and profit outlook reset reflect a strategic pivot to margin discipline, not long-term weakness, amid evolving GLP-1 market dynamics. Despite near-term margin pressure and competitive headwinds, NVO is undervalued by ~36%, per my DCF model, and offers an attractive entry point, especially under $52/share. GLP-1 market shifts—coverage expansion, adherence gains, and next-gen drugs—should expand Novo's addressable market and support long-term growth beyond 2025.
Read More
Novo Nordisk to cut 9,000 jobs
Published: September 10, 2025 by: CNBC Television
Sentiment: Negative
CNBC's Michael Santoli and Melissa Lee discuss pharmaceutical company Novo Nordisk cutting jobs.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
Published: September 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
Novo Nordisk: Job Cuts, Profit Guidance Shock - Why Investors Should Hold Firm
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S announced this morning that it will cut ~9k staff and that the one-off costs of doing so will severely impact profitability in 2025. Novo Nordisk's 2025 has been turbulent, but I believe investors shouldn't panic given the company's long-term strengths. Despite NVO management missteps and external headwinds, semaglutide remains a best-in-class asset with blockbuster potential across obesity, diabetes, and other indications.
Read More
DEADLINE ALERT for FLYW, LMT, SOC, NVO: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Published: September 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
BENSALEM, Pa., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Read More
Novo Nordisk Cuts Around 9,000 Jobs as Weight-Loss Drugmaker Faces Growing Competition
Published: September 10, 2025 by: Investopedia
Sentiment: Negative
Novo Nordisk (NVO) is making big job cuts as the weight-loss drugmaker faces growing competition.
Read More
Is NVO's Major Restructuring Plan an Indication to Sell the Stock?
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
Novo Nordisk's sweeping restructuring plan cuts 9,000 jobs, targets DKK 8 billion in savings, and shifts focus to obesity and diabetes R&D.
Read More
Ozempic Parent Announces 9,000 Job Cuts in Restructuring Plan
Published: September 10, 2025 by: Schaeffers Research
Sentiment: Negative
Pharmaceutical name Novo Nordisk A/S (NYSE:NVO), the maker of weight-loss drugs Wegovy and Ozempic, is in the spotlight today after announcing roughly 9,000 job cuts and slashing its full-year guidance.
Read More
Ozempic Maker Novo Nordisk to Cut 9,000 Jobs
Published: September 10, 2025 by: WSJ
Sentiment: Negative
The company downgraded its guidance for the second time in six weeks as it announced a restructuring plan.
Read More
Our H2 2025 Top Ideas
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
The US economy is showing signs of slowing, with the labor market cooling, consumer sentiment weak, Q3 GDP expected to slow to ~1.3%, and inflation still above the Fed's 2% target. Stagflation is now becoming a real risk. Markets are expensive; the S&P 500 is near all-time highs, and broad-market ETFs like VOO, QQQ, and VTI may only deliver modest returns over the next few years.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Maziar Mike Doustdar
- Employees 77406